- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Breast Cancer With Low to Intermediate HER2 Expression in Italy
Total 4 results
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingMetastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerAustria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
-
Novartis PharmaceuticalsRecruitingHormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA MutationSpain, Italy, Austria
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerCanada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands